hide-icon
Pattern illustration of a DNA helix with a blue background for the OGT corporate brand. (1)
CTA Icon

Do you have a colleague who would like to receive OGT's DNA Dispatch newsletter?

Share this link

Welcome to the latest edition of DNA Dispatch, the quarterly newsletter from OGT, your hybridization experts.

Discover our enhanced OGT website

We're delighted to announce that our OGT website has been updated with exciting new features designed to enhance your experience, including:

  • Improved navigation: designed with you in mind - clearer navigation, faster access
  • New product showcase: updated FISH, NGS and array product searches make it easy to find the perfect product for your lab’s requirements
  • Enhanced support content: including step-by-step protocols, tips and tricks videos and FAQs for each stage of the FISH, NGS and array workflow

Ready to explore the new OGT website? 

Discover our enhanced OGT website Image

Lab Week 2025 Image

Lab Week 2025

We had a fantastic time celebrating our customers during Lab Week 2025. Thank you for all that you do!

In commemoration of Lab Week, we’re excited to introduce a new member of the lab family — Puffy the Background Slayer — named by the competition winner, Fred Hutch Cancer Center.

Missed our GLGC talk?

Want to get caught up on some of the latest research shared at the conference?

We're excited to share a presentation on a custom SureSeq™ panel, the Somatic Myeloid Lymphoid Panel (SMyLyP), given by Laura Semenuk (Queen's University, Kingston, ON, CA) at GLGC in May titled, "SMyLyP: How one integrated laboratory test can detect both molecular and cytogenetic driving alterations across blood cancer." 

Missed our GLGC talk? Image

Hematologic malignancies in focus Image

Hematologic malignancies in focus

Hematological malignancies such as ALL and MDSs are characterized by complex mutations that can vary widely between patients and change over the course of the disease.

Research documenting the frequency and presence of rare mutations in these diseases may help develop future prognostic and treatment response indicators.

See how CytoSure® arrays are driving research in hematological malignancies across the world*:

→ Cryptic rearrangement of the KMT2A gene in a B-cell ALL

→ Genomic landscape of childhood ALL in Malaysia

→ Complex genetic evolution and treatment challenges in myeloid neoplasms

ICYMI: customer scientific posters

Learn more about our SureSeq NGS myeloid genomic solutions at work through two scientific posters, authored by Marzena Wojtaszewska, Coordinator of the Molecular Biology Laboratory, Rzeszow, Poland.

View the scientific posters:

ICYMI: customer scientific posters Image

New article: Sequencing depth vs. sequencing batching Image

New article: Sequencing depth vs. sequencing batching

Our latest article explores the important balance between sequencing depth and sequencing batching in NGS.

By strategically optimizing depth and batching laboratories will be able to achieve cost-efficiency whilst maintaining the sensitivity required for clinical decision-making in cancer genomics.

Don’t forget…Our FAS team can be contacted online with free support advice

 

*Providing links to these publications is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.